Trial Profile

A Phase I, randomized, open-label, active-controlled, three-way treatment trial assessing pharmacokinetics, bioavailability and safety of three doses of CAM2038 q1w (once-weekly) (buprenorphine FluidCrystal injection depot), versus active comparators, intravenous and sublingual buprenorphine, in healthy volunteers under naltrexone blockage

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine (Primary) ; Buprenorphine (Primary) ; Buprenorphine (Primary) ; Buprenorphine (Primary)
Indications Opioid-related disorders
Focus Pharmacokinetics
Sponsors Camurus

21 Oct 2016 According to Braeburn Pharmaceuticals media release, new data will be presented at a joint annual meeting of the International Society of Addiction Medicine (ISAM) and the Canadian Society of Addiction Medicine (CSAM) in Oct 2016.
28 May 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com